PARP10 is a mono-ADP-ribosyltransferase and was reported promoting cardiomyocyte hypertrophy by inhibiting the activity of GSK3β a well-known suppressor of cardiac hypertrophy through mono-ADP-ribosylation (82, 83), suggesting that METTL3 may play a protective role in cardiac hypertrophy, and METTL3-PARP10-GSK3β axis could be a therapeutic target for cardiac hypertrophy. Here, METTL3 is linked to cardiac hypertrophy.